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Association of Lower Fractional Flow Reserve Values With Higher
Risk of Adverse Cardiac Events for Lesions Deferred
Revascularization Among Patients With Acute Coronary Syndrome
Shriti Masrani Mehta, MD; Jeremiah P. Depta, MD,MPHS; Eric Novak, MS; Jayendrakumar S. Patel, MD; Yogesh Patel, MD; David Raymer, MD;
Gabrielle Facey, MD; Alan Zajarias, MD; John M. Lasala, MD, PhD; Jasvindar Singh, MD; Richard G. Bach, MD; Howard I. Kurz, MD
Background-—The safety of deferring revascularization based on fractional ﬂow reserve (FFR) during acute coronary syndrome
(ACS) is unclear. We evaluated the association of FFR and adverse cardiac events among patients with coronary lesions deferred
revascularization based on FFR in the setting of ACS versus non-ACS.
Methods and Results-—The study population (674 patients; 816 lesions) was divided into ACS (n=334) and non-ACS (n=340)
groups based on the diagnosis when revascularization was deferred based on FFR values >0.80 between October 2002 and July
2010. The association and interaction between FFR and clinical outcomes was evaluated using Cox proportional hazards models
within each group (mean follow-up of 4.52.1 years). Subsequent revascularization of a deferred lesion was classiﬁed as a
deferred lesion intervention (DLI), whereas the composite of DLI or myocardial infarction (MI) attributed to a deferred lesion was
designated as deferred lesion failure (DLF). In the non-ACS group, lower FFR values were not associated with any increase in
adverse cardiac events. In the ACS group, every 0.01 decrease in FFR was associated with a signiﬁcantly higher rate of
cardiovascular death, MI, or DLI (hazard ratio [HR], 1.08; 95% conﬁdence interval [CI], 1.03 to 1.12), MI or DLI (HR, 1.09; 95% CI:
1.04 to 1.14), DLF (HR, 1.12; 95% CI, 1.06 to 1.18), MI (HR, 1.07; 95% CI, 1.00 to 1.14), and DLI (HR, 1.12; 95% CI, 1.06 to 1.18).
Conclusion-—Lower FFR values among ACS patients with coronary lesions deferred revascularization based on FFR are associated
with a signiﬁcantly higher rate of adverse cardiac events. This association was not observed in non-ACS patients. ( J Am Heart
Assoc. 2015;4:e002172 doi: 10.1161/JAHA.115.002172)
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T reatment of ischemic myocardium with percutaneouscoronary intervention (PCI) in addition to optimal
medical therapy reduces major adverse cardiac events.1
However, less than half of patients have a noninvasive
ischemic evaluation before revascularization.2 Fractional ﬂow
reserve (FFR) can determine the hemodynamic signiﬁcance
of a coronary lesion by measuring the distal mean coronary
and aortic pressures during maximal hyperemia.2 Previous
studies conducted principally in stable coronary artery
disease (CAD) patients have demonstrated that FFR-guided
revascularization improves clinical outcomes, quality of life,
and cost-efﬁciency.3–5 However, the reliability and safety of
FFR assessment in the setting of acute coronary syndrome
(ACS) is unclear.6 In ACS, microvascular dysfunction from
myocardial injury can persist up to 6 months7 and can impair
maximal hyperemia, leading to an overestimation of FFR.8
Observational studies and post-hoc analyses have suggested
that FFR is reliable9–11 and deferral of lesions based on FFR
is safe in ACS.12–16 A recent expert consensus statement
concluded that FFR is a valid measure in ACS, including
nonculprit lesions in the setting of ST-elevation myocardial
infarction (STEMI).17 However, the statement acknowledged
the effect of microvascular dysfunction on FFR in certain
myocardial infarctions (MIs), as well as the potential for error
in certain clinical situations.17 Thus, the prognostic signiﬁ-
cance of an FFR value may be more uncertain in ACS
compared with stable CAD (ie, non-ACS).6 The goal of this
study was to determine, in a large, real-world cohort, the
predictive ability of FFR for patients with lesions deferred
revascularization based on FFR in the setting of ACS and
non-ACS.
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Methods
Study Design
The study is a retrospective, single-center, observational
study approved by the institutional review board. All patients
provided written informed consent for the procedure.
Study Population
There were 1872 patients that underwent FFR assessment
between October 2002 and July 2010 at our institution. From
2002 to 2008, an FFR value ≥0.75 was used to defer
revascularization based on the DEFER (FFR to Determine
Appropriateness of Angioplasty in Moderate Coronary Ste-
noses) study.3 In 2008, an FFR value >0.80 was used to defer
lesions based on the FAME (Fractional ﬂow reserve versus
Angiography for Multivessel Evaluation) trial.4 Of these 1872
patients, 742 patients with 906 coronary lesions were
deferred revascularization based on FFR. Of the 742 patients,
21 patients or 24 lesions were excluded because of loss of
follow-up after FFR assessment. Furthermore, 47 patients or
68 lesions were excluded because of FFR less than or equal to
0.80. Thus, the ﬁnal population for this study consisted of 674
patients with 816 lesions that were deferred revascularization
based on FFR >0.80 (Figure 1).
Fractional Flow Reserve Assessment
FFR was performed according to standard techniques as
detailed in a previous observational study using this study
population.18 FFR was measured at maximal hyperemia after
administering intracoronary (n=812 lesions) or intravenous
adenosine (n=4 lesions), with the dose determined by the
operator. FFR was not performed on lesions with less than
Thrombolysis In Myocardial Infarction (TIMI) 3 ﬂow.
Clinical Endpoints
Every patient included in the study was followed from the date
of index stenting until March 12, 2013 by reviewing the
medical records and/or telephone interview. All angiograms
were reviewed independently by at least 2 authors. For
patients with follow-up or hospitalizations outside our insti-
tution, the medical records, including angiograms, were
obtained for review. The primary outcome was a composite
of cardiovascular (CV) death, MI, or deferred lesion interven-
tion (DLI). Secondary outcomes included a composite of CV
death or MI and MI or DLI, as well as the individual endpoints
of CV death, MI, MI-lesion, deferred lesion failure (DLF), and
DLI. CV death and MI were deﬁned by the Academic Research
Consortium guidelines.19 DLI was deﬁned as any percuta-
neous coronary intervention (PCI) performed within 5-mm
proximal or distal to, or any coronary artery bypass graft
(CABG) placed distal to, a lesion deferred revascularization
based on the index FFR assessment.18 MI lesion was deﬁned
as any MI that was directly attributable to a lesion deferred
revascularization at the index FFR. DLF was a composite
endpoint of MI lesion or DLI.
Statistical Analysis
The study population was divided into ACS and non-ACS
groups based on clinical diagnosis at the time of index FFR
assessment. The ACS group included unstable angina
(n=257), non-STEMI (NSTEMI; n=70), and STEMI (n=7)
patients. Patient characteristics were compared between
the ACS and non-ACS groups using the Student 2-sample t
test for continuous variables and Fisher’s exact test for
categorical variables. Non-normal and ordinal variables were
reported as median (25th, 75th percentiles) and compared
using the Kruskal–Wallis test. Lesion characteristics were
compared using models developed from generalized estimat-
ing equation (GEE) methods to account for patients having
multiple lesions (clustering). Logistic models were built for
dichotomous lesion characteristics. Lesion characteristics
that were continuous were evaluated by GEE methods using a
normal probability distribution. Skewed continuous lesion
variables were log-transformed preceding model develop-
ment. For all GEE models, robust standard errors were used
when comparing estimates.
Owing to the inherent risk for subsequent adverse cardiac
events post-ACS that persist despite statistical adjustment,
the clinical outcomes between ACS and non-ACS groups were
not compared directly. Instead, the association between FFR
Figure 1. Study population. Flow diagram of the study popula-
tion selection. FFR indicates fractional ﬂow reserve.
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and clinical outcomes was evaluated within each group using
Cox proportional hazards modeling. A marginal Cox model
was used to account for correlated data for patients with
multiple lesions.20 Tests of interaction were performed to
determine whether the FFR association with outcome was
different between ACS and non-ACS groups. Furthermore, for
the outcomes of a composite of CV death, MI or DLI,
composite MI or DLI, and DLF, a multivariable analysis was
performed adjusting for age, diabetes, smoking status,
previous CAD (including PCI or CABG), congestive heart
failure, chronic kidney disease, and myocardial jeopardy
index.21 For the association between FFR and clinical
outcomes as well as tests of interaction, a value of P<0.05
was considered statistically signiﬁcant.22 All statistical anal-
yses were performed using SAS software (version 9.4; SAS
Institute Inc., Cary, NC).
Results
Baseline Characteristics of Study Population
Baseline patient and lesion characteristics of the study
population (674 patients with 816 coronary lesions) are
shown in Tables 1 and 2. Approximately half of the study
population was deferred revascularization post-FFR assess-
ment in the setting of non-ACS (n=340 patients). The
Table 1. Baseline Patient-Level Characteristics
Total Population (n=674) ACS (n=334) Non-ACS (n=340) P Value
Age, y 64.511.1 63.811.9 65.310.2 0.07
Male 380 (56) 180 (54) 200 (59) 0.21
Medical history
Diabetes mellitus 248 (37) 124 (37) 124 (36) 0.87
Hypertension 561 (83) 278 (83) 283 (83) 1.00
Hyperlipidemia 547 (81) 264 (79) 283 (83) 0.17
Ever smoker 344 (51) 183 (55) 161 (47) 0.05
History of CAD 456 (68) 232 (69) 224 (66) 0.32
Previous PCI 307 (46) 165 (49) 142 (42) 0.05
Previous CABG 88 (13) 44 (13) 44 (13) 1.00
Peripheral arterial disease 75 (11) 39 (12) 36 (11) 0.71
Chronic kidney disease 73 (11) 39 (12) 34 (10) 0.54
Congestive heart failure 146 (22) 84 (25)* 62 (18) 0.03
Creatinine level, mg/dL 1.151.22 1.151.24 1.161.20 0.76
Discharge medications after index FFR assessment
OMT
Aspirin 643 (95) 324 (97) 319 (94) 0.06
ACEI/ARB 436 (65) 235 (70)* 201 (59) 0.003
Beta-blocker 516 (77) 265 (79) 251 (74) 0.10
Calcium-channel blocker 205 (30) 109 (33) 96 (28) 0.24
Nitrates 267 (40) 140 (42) 127 (37) 0.24
Statin 543 (81) 268 (80) 275 (81) 0.85
Median number of OMT medications 4 (3, 5) 4 (3, 5) 4 (3, 5) 0.01
Additional medications
Clopidogrel 335 (50) 170 (51) 165 (49) 0.59
Ranolazine 11 (2) 7 (2) 4 (1) 0.38
Warfarin 82 (12) 45 (13) 37 (11) 0.35
Values are shown as absolute numbers (percentages), meanSD, or median (1st, 3rd quartile). ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker;
ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; FFR, fractional ﬂow reserve; OMT, optimal medical therapy; PCI, percutaneous coronary
intervention.
*P<0.05 compared to non-ACS group. All remaining comparisons between the ACS and non-ACS groups were not statistically signiﬁcant.
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remaining patients (n=334) underwent FFR assessment
during an ACS, where 77% of these patients presented with
unstable angina, 21% with NSTEMI, and 2% during STEMI. The
ACS group patients had a higher rate of congestive heart
failure and were discharged more frequently with angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin receptor
Table 2. Baseline Lesion-Level and Procedural Characteristics
Total Population (n=816) ACS (n=411) Non-ACS (n=405) P Value
Coronary vessel location
Left main 56 (7) 29 (7) 27 (7) 0.82
LAD 344 (42) 182 (44) 162 (40) 0.20
Proximal 110 (13) 49 (12) 61 (15) 0.18
Left circumflex 208 (25) 90 (22)* 118 (29) 0.02
Proximal 104 (13) 37 (9)* 67 (17) 0.001
RCA 184 (23) 96 (23) 88 (22) 0.58
Proximal 59 (7) 29 (7) 30 (7) 0.85
Bypass graft 24 (3) 14 (3) 10 (2) 0.43
Multivessel CAD† 430/674 (64) 221/334 (66) 209/340 (61) 0.23
Lesion characteristics
Bifurcation lesion 125 (15) 48 (12)* 77 (19) 0.007
Ostial lesion 173 (21) 102 (25)* 71 (18) 0.01
Previous PCI of lesion 75 (9) 40 (10) 35 (9) 0.60
Median myocardial jeopardy index 6 (2, 6) 4 (2, 6) 6 (2, 6) 0.03
Maximum stenosis, % 5810 5810 5810 0.98
Procedural characteristics
Mean FFR value 0.880.05 0.880.05 0.880.04 0.91
IC adenosine 812 (100) 407 (99) 405 (100) 0.12
Maximum IC dose, lg‡ 120 (120, 180) 120 (120, 180) 120 (96, 180) 0.58
PCI of another lesion 181/674 (27) 97/334 (29) 84/340 (25) 0.22
Values are shown as absolute numbers (percentages), meanSD, or median (1st, 3rd quartile). ACS indicates acute coronary syndrome; CAD, coronary artery disease; FFR, fractional ﬂow
reserve; IC, intracoronary; LAD, left anterior descending artery; PCI, percutaneous coronary intervention; RCA, right coronary artery.
*P<0.05 compared to non-ACS group. All remaining comparisons between the ACS and non-ACS groups were not statistically signiﬁcant.
†
Multivessel CAD was deﬁned as 2 or more signiﬁcant lesions (angiographic percent stenosis ≥50% at the time of FFR assessment.
‡
Maximum IC dose was the highest dose of adenosine given to induce hyperemia during FFR assessment.
Table 3. Clinical Outcomes
Total Population
(n=674 Patients, 816 Lesions)
ACS
(n=334 Patients, 411 Lesions)
Non-ACS
(n=340 Patients, 405 Lesions) P Value
Cardiovascular death/MI/DLI 226 (28) 131 (32) 95 (23) 0.02
Cardiovascular death/MI 98 (15) 65 (19) 33 (10) <0.001
MI/DLI 196 (24) 109 (27) 87 (21) 0.14
DLF 148 (18) 81 (20) 67 (17) 0.28
Cardiovascular death 31 (5) 23 (7) 8 (2) 0.005
MI 73 (11) 47 (14) 26 (8) 0.01
MI lesion 22 (3) 14 (4) 8 (2) 0.20
DLI 144 (18) 78 (19) 66 (16) 0.36
Repeat catheterization 303 (45) 166 (50) 137 (40) 0.02
Parentheses values are expressed in percentage. ACS indicates acute coronary syndrome; DLF, deferred lesion failure; DLI, deferred lesion intervention; MI, myocardial infarction.
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blockers (ARBs) post-FFR assessment, compared to the
non-ACS group. However, both groups were discharged on a
similar median number of optimal medical therapy
medications.23
The left anterior descending artery (LAD) was the predom-
inant vessel location (42%) for deferred lesions. Both groups
had similar rates of multivessel CAD. The ACS group had more
ostial lesions (25% vs. 18%) and fewer bifurcation lesions,
compared to the non-ACS group. The mean FFR value for the
study population was 0.880.05 and was not different
between the ACS and non-ACS groups. Maximal hyperemia
for FFR assessment was induced predominantly using intra-
coronary adenosine with similar maximum doses for both
groups (120 lg). There were no signiﬁcant differences
between patients who were lost to follow-up and those who
were included in the analysis except for the history of CAD
(38% vs. 68%; P=0.008), proximal circumﬂex lesions (27% vs.
13%; P=0.044), FFR value (0.86 vs. 0.88; P=0.033), and
adenosine dose (180 vs. 120; P=0.025).
Clinical Outcomes
Patients were followed for a mean of 4.52.1 years. Clinical
outcomes after deferred revascularization based on FFR are
shown in Table 3. The rate of repeat catheterization was 45%.
Subsequent MI in the lesion that was initially deferred (ie, MI
lesion) accounted for 30% of the total MIs that occurred
during follow-up.
Association Between FFR Values and Outcomes
for ACS and Non-ACS Groups
Table 4 stratiﬁes outcomes based on FFR value ranges and
demonstrates a numerically higher absolute event rate for
each composite outcome within the 0.81 to 0.85 and 0.86 to
0.90 ranges in the ACS group, compared to the non-ACS
group. The associations between FFR values obtained during
maximal hyperemia at the time of index FFR assessment and
clinical outcome within each group assessed by marginal Cox
proportional hazard modeling are shown in Table 5. In the
ACS group, lower FFR values were associated with a
signiﬁcantly higher rate of CV death, MI or DLI (hazard ratio
[HR], 1.08 per 0.01 decrease; 95% conﬁdence interval [CI],
1.03 to 1.12), MI or DLI (HR, 1.09; 95% CI, 1.04 to 1.14), DLF
(HR, 1.12; 95% CI, 1.06 to 1.18), MI (HR, 1.07; 95% CI, 1.00 to
1.14), and DLI (HR, 1.12; 95% CI, 1.06 to 1.18). A trend
toward a lower FFR value being associated with MI lesion in
the ACS group was also observed (HR, 1.12; 95% CI, 0.996 to
Table 4. Outcomes Based on FFR Value
FFR Value
CV Death/MI/DLI MI/DLI MI Lesion/DLI
ACS=No ACS=Yes ACS=No ACS=Yes ACS=No ACS=Yes
0.81 to 0.85 36/133 (27) 58/142 (41) 32/133 (24) 50/142 (35) 26/133 (20) 41/142 (29)
0.86 to 0.90 27/155 (17) 44/140 (31) 25/155 (16) 36/140 (26) 17/155 (11) 25/140 (18)
0.91 to 0.95 28/94 (30) 24/98 (24) 27/94 (29) 19/98 (19) 22/94 (23) 13/98 (13)
0.96+ 4/23 (17) 5/31 (16) 3/23 (13) 4/31 (13) 2/23 (9) 2/31 (6)
Parentheses values are expressed in percentage. ACS indicates acute coronary syndrome; CV, cardiovascular; DLI, deferred lesion intervention; FFR, fractional ﬂow reserve; MI, myocardial
infarction.
Table 5. Cox Proportional HR Per 0.01 Unit Decrease in FFR
ACS HR (95% CI) Non-ACS HR (95% CI) Interaction P Value*
Cardiovascular death/MI/DLI 1.08 (1.03 to 1.12)† 1.01 (0.96 to 1.06) 0.04
Cardiovascular death/MI 1.05 (0.998 to 1.11) 0.98 (0.92 to 1.05) 0.14
MI/DLI 1.09 (1.04 to 1.14)† 1.00 (0.95 to 1.05) 0.01
DLF 1.12 (1.06 to 1.18)† 1.00 (0.95 to 1.06) 0.004
Cardiovascular death 1.04 (0.95 to 1.14) 0.98 (0.82 to 1.17) 0.57
MI 1.07 (1.00 to 1.14)† 0.97 (0.90 to 1.04) 0.05
MI lesion 1.12 (0.996 to 1.26) 0.91 (0.79 to 1.04) 0.02
DLI 1.12 (1.06 to 1.18)† 1.01 (0.95 to 1.06) 0.01
ACS indicates acute coronary syndrome; DLF, deferred lesion failure; DLI, deferred lesion intervention; FFR, fractional ﬂow reserve; HR, hazard ratios; MI, myocardial infarction.
*For comparing HRs between ACS and non-ACS groups.
†
P<0.05 for testing HR=1.
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1.26). The relationship between FFR and each of the clinical
outcomes was found to differ signiﬁcantly between ACS and
non-ACS groups (P<0.05 for each). There was also a trend
toward lower FFR being more likely associated with MI in the
ACS group (P=0.05). In the non-ACS group, lower FFR values
were not associated with an increase in the rate of any of the
clinical outcomes. Using Cox proportional hazard modeling
adjusting for covariates (Figure 2), lower FFR values remained
an independent predictor in the ACS group, but not the non-
ACS group of CV death, MI, or DLI (HR, 1.07; 95% CI, 1.02 to
1.11; interaction, P=0.08), MI or DLI (HR, 1.08; 95% CI, 1.03
to 1.13; interaction, P=0.026), and DLF (HR, 1.11; 95% CI,
1.05 to 1.17; interaction, P=0.005). A sensitivity analysis was
performed including the 21 patients lost to follow-up and did
not show any difference in adjusted HRs.
Discussion
This study demonstrates that, for patients with coronary
lesions deferred revascularization in the setting of ACS based
on non-signiﬁcant FFR values (ie, FFR >0.80), lower FFR
values were associated with a signiﬁcantly higher rate of
adverse cardiac events. After adjustment, lower FFR values
remained an independent predictor of CV death, MI, or DLI,
CV death or MI, and DLF among ACS patients. The
association between lower FFR values and adverse clinical
outcomes was not observed for any of the composite or
individual endpoints among non-ACS patients deferred revas-
cularization based on FFR. One third of the subsequent MIs
that occurred during follow-up were attributable to the lesion
initially deferred based on FFR assessment. Our study
provides new evidence that lesions with lower FFR values
deferred in the setting of ACS are at higher risk for
subsequent adverse cardiac events.
In the DEFER and FAME trials, when compared with
angiographic guidance, FFR-guided selection of lesions for the
deferral or performance of PCI improved clinical outcomes,
although the majority of patients included in those trials had
stable CAD.3,4 FFR can improve the diagnostic efﬁciency over
angiography alone in the setting of ACS,24 especially in the
presence of multivessel CAD. However, the reliability of FFR
assessment of lesions during ACS has been controversial.6
FFR assessment is performed by inducing maximal hyperemia
to determine the physiological signiﬁcance of a coronary
stenosis.25 Compared with stable CAD, ACS is a dynamic
process with the potential for lesion instability and microvas-
cular dysfunction that has been found in patients with MI to
involve both infarct-related and non-infarct-related myocardial
Figure 2. Adjusted hazard ratios for the association between FFR and clinical outcomes. A marginal Cox
proportional hazard model was performed to adjust for age, diabetes, smoking status, previous coronary
artery disease (including PCI or CABG), congestive heart failure, chronic kidney disease, and myocardial
jeopardy index. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft; DLF, deferred
lesion failure; DLI, deferred lesion intervention; FFR, fractional ﬂow reserve; HR, hazard ratios; MI,
myocardial infarction; PCI, percutaneous coronary intervention.
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segments, and that persists for a poorly deﬁned period,
possibly up to 6 months.7 Microvascular dysfunction has also
been demonstrated in patients with unstable angina, where
vasoconstriction and increased distal microvascular resis-
tance reduces coronary blood ﬂow.26 Theoretically, when
contrasted with intact microvascular function, an inability to
induce maximal coronary hyperemia could lead to a smaller
gradient and a higher FFR value for a given stenosis.8,27
Beyond microvascular dysfunction, lower oxygen consumption
in an infarcted territory, abnormal vasomotion of the epicar-
dial and resistance vessels distal to a coronary thrombosis,
and/or obstruction of the microvasculature, could limit
myocardial blood ﬂow and affect FFR assessment.9 Therefore,
there are multiple potential mechanisms that could adversely
inﬂuence the reliability of FFR in the setting of ACS. Given
these considerations and the fact that the decision to
revascularize is largely based on an accepted ischemic
threshold of 0.80,17 it appears possible that a nonsigniﬁcant
FFR value that is close to the threshold in a patient with ACS
could underestimate lesion physiological signiﬁcance and
potential for causing ischemia.4,5 Not inconsistent with our
data, a recent meta-analysis suggested that FFR has been
shown to have a continuous and independent relationship
with clinical outcomes, with the suggestion that the FFR
threshold for composite major adverse CV events in ACS
patients may exceed the current threshold of 0.80.28
Several studies have previously examined the reliability of
FFR for lesion assessment in the setting of ACS.9–11 A study
of 57 patients who suffered an MI ≥6 days before FFR
assessment determined that an FFR <0.75 had an 82%
sensitivity and 87% speciﬁcity for detecting inducible ischemia
determined by stress single-photon emission computed
tomography (SPECT) imaging.9 Despite concluding that an
FFR value of 0.75 was valid 6 days after acute MI, the
investigators cautioned that the results should not be
extrapolated to FFR measurements obtained during the acute
phase of an MI.9 A prospective study performed SPECT, FFR,
and PCI of the infarct-related artery 3.71.3 days after an MI
(73% STEMI; 27% NSTEMI) in 48 patients and then repeated
SPECT imaging 11 weeks later to assess for reversibility after
revascularization.10 The sensitivity and speciﬁcity of an FFR
value ≤0.75 to accurately identify reversible ischemia on
SPECT were 88% and 50%, respectively.10 The ﬁndings of
these studies provided information regarding FFR post-ACS,
but they may not be generalizable to our study, given that FFR
measurements in the ACS group in our study were obtained
during the acute phase of a coronary event.
To examine the reproducibility of an FFR value measured
acutely to one measured after recovery from ACS, a
prospective study measured FFR in 112 nonculprit lesions
in AMI patients (75% STEMI) at the time of clinical
presentation and 354 days later.11 Only 2 patients with
an FFR value >0.80 at the time of their MI had an FFR value
<0.75 at follow-up.11 Given that microvascular dysfunction
may persist for an unknown interval and possibly up to
6 months after an MI,7 the follow-up time between FFR
measurements in that study may not have been sufﬁcient for
full recovery and restoration of microcirculatory function.
Observational studies and post-hoc analyses of random-
ized trials have suggested that FFR-guided revascularization is
safe in ACS.12–16 In FAME, 33% of patients (n=328) were
studied in the setting of ACS (unstable angina or NSTEMI),
where 178 and 150 patients were randomized to angio-
graphic- or FFR-guided PCI, respectively.12 The beneﬁt of FFR-
guided PCI, compared with angiography alone, appeared
similar for the ACS and stable CAD (n=677) groups.12 Despite
a higher rate of adverse cardiac events in ACS patients,
compared to stable CAD patients, none of the MIs during
follow-up reportedly occurred in the index lesion deferred PCI
based on FFR.4,12 Nevertheless, it is notable that the number
of ACS patients in FAME undergoing FFR-guided revascular-
ization was relatively small with shorter follow-up, which, as
acknowledged by the investigators, may have limited the
power of the study to show differences among subgroups.
Several additional smaller observational studies have
assessed the clinical outcomes for lesions that were deferred
revascularization in the setting of ACS.13–16 Three of these
studies, including a total of less than 250 ACS patients,
concluded that there were similar outcomes for patients
deferred PCI based on FFR in the setting of ACS or non-
ACS.14,15 A more recent study of 162 patients deferred PCI
based on an FFR ≥0.75 in the setting of ACS (60%) and non-ACS
(40%) demonstrated that patients with an FFR value of 0.75 to
0.85 and microvascular dysfunction (measured by an abnormal
corrected thrombolysis in myocardial infarction frame count
[CTFC]) had a signiﬁcantly higher rate of adverse cardiac
events, compared with patients with an FFR value >0.85 and
normal CTFC.16 Similar to our study, lower FFR values in their
analysis were an independent predictor of later adverse cardiac
events (HR, 1.09; 95% CI, 1.01 to 1.19; P=0.03).16
Previous studies assessing the clinical safety and reliability
of FFR for deferring revascularization among patients with
ACS were limited by small sample sizes13–16 and by lesion
assessment by FFR beyond the acute phase of ACS.12 Our
study represents one of the largest studies on the clinical
outcomes of lesions deferred PCI based on FFR, where half of
the study population underwent assessment during ACS.
Compared with previous studies,12–16 our study has a
signiﬁcantly higher rate of adverse cardiac events, which
may be secondary to the nonselected, real-world study
population and the longer follow-up (mean 4.52.1 years).
Our study population also included patients with multivessel
disease (64%) and left main lesions (7%), many of which were
excluded from other studies.12,13 The recent prospective
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randomized Fractional ﬂow reserve versus Angiography in
guiding Management to Optimize oUtcomeS in NSTEMI
(FAMOUS-NSTEMI) trial demonstrated that routine FFR mea-
surement is feasible in NSTEMI patients, but was not powered
to assess for differences in clinical outcomes compared to
angiographic-guided care.6 Further prospective evidence is
needed to fully elucidate the reliability, reproducibility, and
safety of FFR measurements in ACS.
Study Limitations
This is a retrospective, observational study conducted at a
large, single urban tertiary referral center. The possibility of
reporting bias and the absence of an independent clinical
events committee are potential limitations. A small number of
patients (n=21) were excluded from the study population
because of loss to follow-up. The results may not be general-
izable to different populations and hospitals of different sizes
and/or level of acuity. In the ACS group, culprit versus
nonculprit lesions were distinguished based on the operator’s
judgment and this determination was therefore subjective,
similar to common clinical practice. However, FFR was not
performed on any lesion with less than TIMI 3 ﬂow. Moreover,
there may be unmeasured confounders or selection bias that
contributed to differences in clinical outcomes between the
ACS and non-ACS groups. Although FFR has been well validated
as a measure of ischemia, it may have limited relevance for
predicting the stability of a plaque. The study cannot determine
the safety of deferring lesions based on FFR versus angio-
graphic-guidance in the setting of ACS. Although our study
demonstrated an association between lower FFR values and
worse clinical outcomes in ACS patients, the clinical beneﬁts of
FFR-guided PCI over angiography alone, as demonstrated in
FAME,12 may still persist in an ACS population.
Conclusions
For patients with intermediate severity coronary lesions that
are deferred revascularization in the setting of ACS based on
FFR >0.80, lower FFR values are associated with a signiﬁ-
cantly higher rate of adverse cardiac events. The association
between lower FFR values and adverse clinical outcomes was
not observed among deferred lesions in non-ACS patients.
Further study is needed to determine the reliability and safety
of deferring lesions with relatively lower FFR values in the
setting of ACS based on the currently accepted FFR threshold
validated in predominantly non-ACS patients.
Disclosures
Dr Zajarias is a steering committee member of the Partner 2
trial. Dr Lasala is on a Boston Scientiﬁc Advisory Board. Dr
Singh is a consultant for Abbott Vascular, Boston Scientiﬁc,
and Volcano Corp and is on the speakers’ bureaus of, or
receives honoraria from, The Medicines Company, Medtronic
Vascular, Volcano Corp, and St. Jude Medical Corp. Dr Bach
receives research grants from Bristol-Myers Squibb, Eli Lilly,
GlaxoSmithKline, Merck, and Schering-Plough and is a
consultant (clinical event committee activity only) for Eli Lilly,
Novo Nordisk, and Pﬁzer.
References
1. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM,
Weintraub WS, O’Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J,
Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz
RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE;
Investigators C. Optimal medical therapy with or without percutaneous
coronary intervention to reduce ischemic burden: results from the clinical
outcomes utilizing revascularization and aggressive drug evaluation (COUR-
AGE) trial nuclear substudy. Circulation. 2008;117:1283–1291.
2. Park SJ, Ahn JM, Kang SJ. Paradigm shift to functional angioplasty: new
insights for fractional ﬂow reserve- and intravascular ultrasound-guided
percutaneous coronary intervention. Circulation. 2011;124:951–957.
3. Pijls NH, van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, van’t Veer
M, B€ar F, Hoorntje J, Koolen J, Wijns W, de Bruyne B. Percutaneous coronary
intervention of functionally nonsigniﬁcant stenosis: 5-year follow-up of the
DEFER study. J Am Coll Cardiol. 2007;49:2105–2111.
4. Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, van’t Veer M,
Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA,
De Bruyne B; Investigators FS. Fractional ﬂow reserve versus angiography for
guiding percutaneous coronary intervention in patients with multivessel
coronary artery disease: 2-year follow-up of the FAME (fractional ﬂow reserve
versus angiography for multivessel evaluation) study. J Am Coll Cardiol.
2010;56:177–184.
5. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N,
M€obius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstrøm T, Oldroyd
KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB,
J€uni P, Fearon WF; Investigators FT. Fractional ﬂow reserve-guided PCI versus
medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–
1001.
6. Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, Junejo S,
Ahmed N, Lee M, Shaukat A, O’Donnell A, Nam J, Briggs A, Henderson R,
McConnachie A, Berry C. Fractional ﬂow reserve vs. angiography in guiding
management to optimize outcomes in non-ST-segment elevation myocardial
infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. Eur
Heart J. 2015;36:100–111.
7. Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Reduced
coronary vasodilator function in infarcted and normal myocardium after
myocardial infarction. N Engl J Med. 1994;331:222–227.
8. Claeys MJ, Bosmans JM, Hendrix J, Vrints CJ. Reliability of fractional ﬂow
reserve measurements in patients with associated microvascular dysfunction:
importance of ﬂow on translesional pressure gradient. Catheter Cardiovasc
Interv. 2001;54:427–434.
9. De Bruyne B, Pijls NH, Bartunek J, Kulecki K, Bech JW, De Winter H, Van
Crombrugge P, Heyndrickx GR, Wijns W. Fractional ﬂow reserve in patients
with prior myocardial infarction. Circulation. 2001;104:157–162.
10. Samady H, Lepper W, Powers ER, Wei K, Ragosta M, Bishop GG, Sarembock IJ,
Gimple L, Watson DD, Beller GA, Barringhaus KG. Fractional ﬂow reserve of
infarct-related arteries identiﬁes reversible defects on noninvasive myocardial
perfusion imaging early after myocardial infarction. J Am Coll Cardiol.
2006;47:2187–2193.
11. Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, Barbato E,
Hamilos M, Mangiacapra F, Heyndrickx GR, Wijns W, Pijls NH, De Bruyne B.
Fractional ﬂow reserve for the assessment of nonculprit coronary artery
stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv.
2010;3:1274–1281.
12. Sels JW, Tonino PA, Siebert U, Fearon WF, Van’t Veer M, De Bruyne B, Pijls NH.
Fractional ﬂow reserve in unstable angina and non-st-segment elevation
myocardial infarction experience from the FAME (fractional ﬂow reserve
versus angiography for multivessel evaluation) study. JACC Cardiovasc Interv.
2011;4:1183–1189.
13. Leesar MA, Abdul-Baki T, Akkus NI, Sharma A, Kannan T, Bolli R. Use of
fractional ﬂow reserve versus stress perfusion scintigraphy after unstable
DOI: 10.1161/JAHA.115.002172 Journal of the American Heart Association 8















 at Washington University on August 22, 2015http://jaha.ahajournals.org/Downloaded from 
angina. Effect on duration of hospitalization, cost, procedural characteristics,
and clinical outcome. J Am Coll Cardiol. 2003;41:1115–1121.
14. Potvin JM, Rodes-Cabau J, Bertrand OF, Gleeton O, Nguyen CN, Barbeau G,
Proulx G, De Larochelliere R, Dery JP, Batalla N, Dana A, Facta A, Roy L.
Usefulness of fractional ﬂow reserve measurements to defer revascularization
in patients with stable or unstable angina pectoris, non-ST -elevation and ST-
elevation acute myocardial infarction, or atypical chest pain. Am J Cardiol.
2006;98:289–297.
15. Fischer JJ, Wang XQ, Samady H, Sarembock IJ, Powers ER, Gimple LW,
Ragosta M. Outcome of patients with acute coronary syndromes and
moderate coronary lesions undergoing deferral of revascularization based on
fractional ﬂow reserve assessment. Catheter Cardiovasc Interv. 2006;68:544–
548.
16. EsenAM, Acar G, EsenO, Emiroglu Y, AkcakoyunM, Pala S, Karapinar H, Kargin R,
Barutcu I, Turkmen M. The prognostic value of combined fractional ﬂow reserve
and TIMI frame count measurements in patients with stable angina pectoris and
acute coronary syndrome. J Interv Cardiol. 2010;23:421–428.
17. Lotﬁ A, Jeremias A, Fearon WF, Feldman MD, Mehran R, Messenger JC, Grines
CL, Dean LS, Kern MJ, Klein LW. Expert consensus statement on the use of
fractional ﬂow reserve, intravascular ultrasound, and optical coherence
tomography: a consensus statement of the Society of Cardiovascular
Angiography and Interventions. Catheter Cardiovasc Interv. 2014;83:509–518.
18. Depta JP, Patel JS, Novak E, Masrani SK, Raymer D, Facey G, Patel Y, Zajarias
A, Lasala JM, Singh J, Bach RG, Kurz HI. Outcomes of coronary stenoses
deferred revascularization for borderline versus nonborderline fractional ﬂow
reserve values. Am J Cardiol. 2014;113:1788–1793.
19. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG,
Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW,
Serruys PW; Academic Research C. Clinical end points in coronary stent trials:
a case for standardized deﬁnitions. Circulation. 2007;115:2344–2351.
20. Lee EW, Wei LJ, Amato DA, Leurgans S. Cox-type regression analysis for large
numbers of small groups of correlated failure time observations. In: Klein JP,
Goel PK, eds. Survival Analysis: State of the Art. Dordrecht, Netherlands:
Kluwer Academic Publishers; 1992:237–247.
21. Califf RM, Phillips HR III, Hindman MC, Mark DB, Lee KL, Behar VS, Johnson
RA, Pryor DB, Rosati RA, Wagner GS, Harrell FE. Prognostic value of a coronary
artery Jeopardy score. J Am Coll Cardiol. 1985;5:1055–1063.
22. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3rd
ed. Hoboken, N.J: John Wiley & Sons; 2003.
23. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson
M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz
S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS,
Mancini GB, Weintraub WS; Group CTR. Optimal medical therapy with or
without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516.
24. Carrick D, Behan M, Foo F, Christie J, Hillis WS, Norrie J, Oldroyd KG, Berry C.
Usefulness of fractional ﬂow reserve to improve diagnostic efﬁciency in
patients with non-ST elevation myocardial infarction. Am J Cardiol.
2013;111:45–50.
25. Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek JKJJ,
Koolen JJ. Measurement of fractional ﬂow reserve to assess the functional
severity of coronary-artery stenoses. N Engl J Med. 1996;334:1703–1708.
26. Marzilli M, Sambuceti G, Fedele S, L’Abbate A. Coronary microcirculatory
vasoconstriction during ischemia in patients with unstable angina. J Am Coll
Cardiol. 2000;35:327–334.
27. Cuculi F, DeMaria GL, Meier P, Dall’Armellina E, de Caterina AR, Channon KM,
Prendergast BD, Choudhury RC, Forfar JC, Kharbanda RK, Banning AP. Impact
of microvascular obstruction on the assessment of coronary ﬂow reserve,
index of microcirculatory resistance, and fractional ﬂow reserve after ST-
segment elevation myocardial infarction. J Am Coll Cardiol. 2014;64:1894–
1904.
28. Johnson NP, Tόth GG, Lai D, Zhu H, Acar G, Agostini P, Appelman Y, Arslan F,
Barbato E, Chen SL, Di Seraﬁno L, Dόminguez-Franco AJ, DuPouy P, Esen AM,
Esen OB, Hamilos M, Iwasaki K, Jensen LO, Jimenez-Navarro MF, Katritsis DG,
Kocaman SA, Koo BK, Lόpez-Palop R, Lorin JD, Miller LH, Muller O, Nam CW,
Oud N, Puymirat E, Rieber J, Rioufol G, Rodes-Cabau J, Sedlis SP, Takeishi Y,
Tonino PA, Van Belle E, Verna E, Werner GS, Fearon WF, Pijls NH, De Bruyne B,
Gould KL. Prognostic value of fractional ﬂow reserve: linking physiologic
severity to clinical outcomes. J Am Coll Cardiol. 2014;64:1651–1654.
DOI: 10.1161/JAHA.115.002172 Journal of the American Heart Association 9















 at Washington University on August 22, 2015http://jaha.ahajournals.org/Downloaded from 
Howard I. Kurz
Raymer, Gabrielle Facey, Alan Zajarias, John M. Lasala, Jasvindar Singh, Richard G. Bach and 
Shriti Masrani Mehta, Jeremiah P. Depta, Eric Novak, Jayendrakumar S. Patel, Yogesh Patel, David
Syndrome
Events for Lesions Deferred Revascularization Among Patients With Acute Coronary 
Association of Lower Fractional Flow Reserve Values With Higher Risk of Adverse Cardiac
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.115.002172
2015;4:e002172; originally published August 19, 2015;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/4/8/e002172
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 at Washington University on August 22, 2015http://jaha.ahajournals.org/Downloaded from 
